Transplant Anti-Rejection Drugs Studied
Posted on: Tuesday, 29 January 2008, 15:00 CST
U.S. scientists are using stem cells from kidney donors' bone marrow to possibly eliminate the need for anti-rejection drugs in transplant patients.
After a transplant surgery, anti-rejection drugs for the organ recipient are required but such drugs also present the potential of infection, heart disease and cancer.
If it's successfully, the new research -- led by Dr. Joshua Miller of Northwestern University's Feinberg School of Medicine -- would mean a dramatic change in post-transplant procedures.
Northwestern, one of four U.S. facilities involved in the research, has received a four-year, $2.5 million grant from the National Institutes of Health to enroll 20 patients in the study.
Source: United Press International
Related Articles
- AST on Capitol Hill to Promote Transplant Drug Extension Provision With Senate as Part of Health Care Reform
- Stanford Study Finds Transplant Patient Thrives Two Years After Stopping Immunosuppressive Drugs
- Dade Behring Launches Tacrolimus Test on Its Dimension(R), V-Twin(R), and Viva-E(TM) Systems; Addition Expands Transplant Rejection Monitoring Test Portfolio
- Ariz. Pays for Medicare Mess: Governor Orders $500K in Emergency Funds
- New Drug May Blunt Post-Transplant Cancer
- Pharmacogenetics As a Tool to Enable the Individualisation of Immunosuppressive Drug Treatment for Organ Transplantation
- Experts Study Hand, Face Transplant Drugs
- Radically New Anti-Rejection Drug Shown to Offer Safe Control of Immune System in Stanford Study
- New drug could aid transplant patients
- Drug May Help Heart Transplant Patients
 |
 |
User Comments (0)
RSS Feeds